Related Experiment Video
Updated: Jul 11, 2026
05:28
A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
Published on: August 27, 2019
Tamibarotene.
Ishido Miwako1, Hiroyuki Kagechika
1R&R Inc., Tokyo, Japan.
Drugs of Today (Barcelona, Spain : 1998)
|October 11, 2007
Summary
Tamibarotene, a synthetic retinoid, is approved for acute promyelocytic leukemia (APL) in Japan. It shows greater potency and stability than ATRA, with milder side effects and potential for other diseases.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL) is a distinct subtype of leukemia.
- All-trans retinoic acid (ATRA) is a standard first-line treatment for APL.
- There is a need for more effective and stable retinoid therapies for APL.
Purpose of the Study:
- To review the mechanisms of action, chemical properties, and pharmacokinetics of tamibarotene.
- To discuss the efficacy and safety of tamibarotene in APL treatment.
- To explore the potential of tamibarotene in other diseases.
Main Methods:
- Review of preclinical and clinical data on tamibarotene.
- Comparison of tamibarotene with ATRA in terms of chemical stability, potency, and clinical outcomes.
- Analysis of pharmacokinetic profiles and adverse effects.
Main Results:
- Tamibarotene is a potent inducer of differentiation in APL cells, more stable and effective than ATRA.
- Tamibarotene maintains sustained plasma levels and exhibits milder adverse effects compared to ATRA.
- Clinical trials demonstrate tamibarotene's efficacy in relapsed APL patients.
Conclusions:
- Tamibarotene represents a significant advancement in APL treatment, offering improved efficacy and tolerability.
- Its unique properties warrant further investigation for potential applications in multiple myeloma and Crohn's disease.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...